Clarifications From Bharat Biotech On Covaxin Likely By Weekend: WHO
NDTV
The Technical Advisory Group met October 26 and "decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine".
The World Health Organisation on Wednesday said it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine -- Covaxin -- and will meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing. WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure.pic.twitter.com/hIS117jvty
"WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure," the WHO tweeted.
The Technical Advisory Group met October 26 and "decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine".
